JMPWA
TEVA icon

JP Morgan Private Wealth Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

JP Morgan Private Wealth Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$209K Buy
20,495
+5,093
+33% +$47.4K ﹤0.01% 1616
2023
Q2 		$116K Sell
15,402
-4,678
-23% -$37.9K ﹤0.01% 1432
2023
Q1 		$178K Sell
20,080
-892
-4% -$8.82K ﹤0.01% 1851
2022
Q4 		$191K Buy
20,972
+3,316
+19% +$28.9K ﹤0.01% 1833
2022
Q3 		$142K Buy
17,656
+578
+3% +$5.11K ﹤0.01% 1852
2022
Q2 		$128K Sell
17,078
-1,030
-6% -$8.97K ﹤0.01% 1862
2022
Q1 		$170K Buy
18,108
+132
+0.7% +$1.1K ﹤0.01% 1932
2021
Q4 		$144K Sell
17,976
-1,968
-10% -$17.8K ﹤0.01% 1932
2021
Q3 		$194K Sell
19,944
-8,936
-31% -$83.7K ﹤0.01% 1868
2021
Q2 		$286K Buy
28,880
+11,588
+67% +$123K ﹤0.01% 1691
2021
Q1 		$200K Buy
+17,292
New +$198K ﹤0.01% 1695
2019
Q1 		– Sell
-15,018
Closed -$232K – 1510
2018
Q4 		$232K Buy
15,018
+1,298
+9% +$26.6K ﹤0.01% 1276
2018
Q3 		$296K Sell
13,720
-6,390
-32% -$148K ﹤0.01% 1301
2018
Q2 		$489K Buy
20,110
+4,657
+30% +$95K ﹤0.01% 1014
2018
Q1 		$265K Sell
15,453
-1,376
-8% -$26.9K ﹤0.01% 1088
2017
Q4 		$319K Sell
16,829
-5,146
-23% -$77.4K ﹤0.01% 1034
2017
Q3 		$387K Sell
21,975
-1,483
-6% -$33.4K ﹤0.01% 944
2017
Q2 		$780K Sell
23,458
-19,753
-46% -$611K 0.01% 684
2017
Q1 		$1.39M Buy
43,211
+3,148
+8% +$107K 0.01% 548
2016
Q4 		$1.45M Sell
40,063
-11,069
-22% -$442K 0.01% 503
2016
Q3 		$2.35M Sell
51,132
-9,423
-16% -$492K 0.02% 403
2016
Q2 		$3.04M Sell
60,555
-3,220
-5% -$171K 0.03% 354
2016
Q1 		$3.41M Buy
63,775
+12,657
+25% +$743K 0.03% 305
2015
Q4 		$3.36M Buy
51,118
+19,166
+60% +$1.18M 0.03% 280
2015
Q3 		$1.8M Sell
31,952
-5,826
-15% -$378K 0.02% 351
2015
Q2 		$2.23M Buy
37,778
+1,965
+5% +$121K 0.03% 349
2015
Q1 		$2.23M Sell
35,813
-4,328
-11% -$252K 0.03% 356
2014
Q4 		$2.31M Buy
40,141
+1,629
+4% +$90.8K 0.03% 356
2014
Q3 		$2.07M Buy
38,512
+8,079
+27% +$428K 0.03% 367
2014
Q2 		$1.59M Buy
30,433
+1,661
+6% +$84.9K 0.03% 331
2014
Q1 		$1.52M Buy
28,772
+1,830
+7% +$84.6K 0.03% 327
2013
Q4 		$1.08M Sell
26,942
-540
-2% -$21.3K 0.02% 332
2013
Q3 		$1.04M Sell
27,482
-21,644
-44% -$844K 0.02% 326
2013
Q2 		$1.93M Buy
+49,126
New +$1.91M 0.05% 246

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

JP Morgan Private Wealth Advisors's TEVA Position: Q3 2023 in Review

JP Morgan Private Wealth Advisors increased its Teva Pharmaceuticals (TEVA) stake by 33% in Q3 2023, buying an estimated $47.4K and bringing the position to 20,495 shares worth $209K. The position accounts for ﹤0.01% of the portfolio, ranked #1616.

JP Morgan Private Wealth Advisors first reported a position in TEVA in Q2 2013 and has held it in 34 quarters since. The position peaked at $3.41M in Q1 2016. 435 funds tracked by Wall St. Rank hold TEVA as of Q3 2023.

  • JP Morgan Private Wealth Advisors held 20,495 shares of Teva Pharmaceuticals worth $209K as of Q3 2023.
  • JP Morgan Private Wealth Advisors bought 5,093 Teva Pharmaceuticals shares in Q3 2023, an estimated $47.4K.
  • Teva Pharmaceuticals made up ﹤0.01% of JP Morgan Private Wealth Advisors's portfolio in Q3 2023, its #1616 holding.
  • JP Morgan Private Wealth Advisors first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 34 quarters since.
  • JP Morgan Private Wealth Advisors's Teva Pharmaceuticals position peaked at $3.41M in Q1 2016.
  • 435 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2023.

Based on JP Morgan Private Wealth Advisors's 13F filing for Q3 2023, filed 8 Nov 2023.